Abstract
Thrombopoietin (THPO) is a circulatory cytokine that plays an important role in platelet production. The presence of anti-THPO antibody relates to thrombocytopenia and is rarely seen in hematopoietic and autoimmune diseases. To date, there had been no reports that focused on the anti-THPO antibody in patients with type 2 diabetes mellitus (T2DM). To evaluate prevalence of the anti-THPO antibody in patients with T2DM and the relationship between anti-THPO antibody and platelet count, a cross-sectional study was performed on 82 patients with T2DM. The anti-THPO antibody was measured by ELISA using preserved sera and detected in 13 patients. The average platelet count was significantly lower in patients with the anti-THPO antibody than in those without the anti-THPO antibody. Multivariate linear regression analyses showed a significant relationship between the anti-THPO antibody and platelet count, after adjusting for other variables. To our best knowledge, this was the first report on the effect of the anti-THPO antibody on platelet count in patients with T2DM. Further investigation is needed to validate the prevalence and pathological significance of the anti-THPO antibody in patients with T2DM.
Highlights
Thrombopoietin (THPO) is a circulatory cytokine that is produced mainly by the liver [1] and plays an important role in the proliferation and differentiation of megakaryocyte progenitors [2].Proplatelet processes are formed from megakaryocytes, which later fragment into platelets [3].The importance of THPO signaling in maintaining the number of circulating platelets had been reported, based on the reduced number of platelets and megakaryocytes after administration of the anti-THPO antibody in THPO knockout mice [4] and in mice with the THPO knockout-like phenotype [5]
Molecules 2020, 25, 1667 purpura [8], idiopathic thrombocytopenia purpura (ITP) [9], systemic lupus thrombocytopenic erythematosus (SLE) [10,11], in those treated with recombinant human THPO (rhTHPO) [12,13] and recombinant human erythropoietin
[10,11], against the interaction between rhTHPO. They reported that, using the in those treated with rhTHPO [12,13] and recombinant human erythropoietin [14]
Summary
Takuya Fukuda 1 , Masahide Hamaguchi 1, * , Takafumi Osaka 1,2 , Yoshitaka Hashimoto 1 , Emi Ushigome 1 , Mai Asano 1 , Masahiro Yamazaki 1 , Eriko Fukuda 3,4 , Kei Yamaguchi 3,4 , Koji Ogawa 4 , Naoki Goshima 3,4 and Michiaki Fukui 1.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
